Search Result

Isoforms Recommended:	MAP4K1/HPK1

Results for "

HPK1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bcr-Abl (1) Drug Intermediate (2) E3 Ligase Ligand-Linker Conjugates (1) ERK (1) FLT3 (1) HOXA (1) IFNAR (4) Interleukin Related (13) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (8) MAP4K (87) PROTACs (10) Small Interfering RNA (siRNA) (3) Src (2) Target Protein Ligand-Linker Conjugates (2)
By Research Areas:	Cancer (85) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (34) Metabolic Disease (1) Neurological Disease (1)
Click Chemistry:	PROTAC Synthesis (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148847

HPK1-IN-32	MAP4K	Cancer
HPK1-IN-32 is a potent and selective *HPK1* inhibitor with an IC₅₀ of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases ^[1].

HY-138568

HPK1-IN-3	MAP4K	Inflammation/Immunology
HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC₅₀ of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC₅₀ of 108 nM in human peripheral blood mononuclear cells (PBMCs) ^[1].

HY-138742

HPK1-IN-7	MAP4K	Cancer
HPK1-IN-7 is a potent, orally active *HPK1* (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC₅₀=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1 ^[1].

HY-163372

*PROTAC HPK1* Degrader-1**	PROTACs MAP4K	Cancer
PROTAC HPK1 Degrader-1 (Compound B1) is a potent *HPK1* degrader with DC₅₀ value of 1.8 nM. PROTAC HPK1 Degrader-1 inhibits phosphorylation of the SLP76 protein with IC₅₀ value of 496.1 nM. PROTAC HPK1 Degrader-1 is a bona fide *HPK1-PROTAC* degrader, which provided a potential tool for further HPK1 investigation in TCR signaling ^[1].

HY-144093

HPK1/GLK-IN-1	MAP4K	Infection
HPK1/GLK-IN-1 is a *HPK1* and GLK inhibitor. HPK1/GLK-IN-1 (compound 38) potently inhibits GLK with an IC₅₀ of  33 nM . HPK1-IN-26 can be used for the research of animal pathogen infection ^[1].

HY-W058423

6-Bromo-3-fluoropyridine-2-carbaldehyde	Drug Intermediate MAP4K	Cardiovascular Disease Inflammation/Immunology
6-Bromo-3-fluoropyridine-2-carbaldehyde (synthetic intermediate of Compound I-90) is a synthetic intermediate. 6-Bromo-3-fluoropyridine-2-carbaldehyde can be used in the synthesis of *HPK1* inhibitors. 6-Bromo-3-fluoropyridine-2-carbaldehyde is applicable to research on immune diseases and hematological diseases ^[1].

HY-135892

GNE-1858 3 Publications Verification	MAP4K	Inflammation/Immunology
GNE-1858 is a potent and ATP-competitive hematopoietic progenitor kinase-1 (HPK1) inhibitor, with IC₅₀s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA, respectively ^[1].

HY-144088

ZYF0033 2 Publications Verification HPK1-IN-22	MAP4K	Inflammation/Immunology Cancer
ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a ⁺CD8 ⁺ T cells, but not T cells, PD-1 ⁺CD8 ⁺ T cells, TIM-3 ⁺CD8 ⁺ Infiltration of T cells and LAG3 ⁺CD8 ⁺ T cells was reduced ^[1] .

HY-157149

DS21150768	MAP4K	Cancer
DS21150768 is a potent, orally active *HPK1* inhibitor. DS21150768 shows potent activity to enhance T-cell function. DS21150768 has anticancer effects ^[1].

HY-173006

AZ3246	MAP4K Interleukin Related	Cancer
AZ3246 is an orally active and selective inhibitor of *HPK1* with an IC₅₀ of < 3 nM. AZ3246 induces IL-2 secretion in T cells with an EC₅₀ of 90 nM. AZ3246 is a low-clearance antitumor compound that can be used for the study of breast cancer ^[1].

HY-175551

HPK1 ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates MAP4K	Cancer
HPK1 ligand-Linker Conjugate 1 is a synthesized target protein ligand-linker conjugate that can be used for synthesis of PROTACs, such as PROTAC HPK1 Degrader-5 (HY-175547). PROTAC HPK1 Degrader-5 is a potent and orally active HPK1 PROTAC degrader with anti-tumor activity ^[1].

HY-159643

NDI-101150	MAP4K IFNAR Interleukin Related	Inflammation/Immunology Cancer
NDI-101150 is an orally active, potent and selective hematopoietic progenitor cell kinase 1 (HPK1) inhibitor with an IC₅₀ of 0.7 nM. NDI-101150 blocks HPK1-mediated negative regulation of immune receptor signaling, inhibits immunosuppression of T cell activation, enhances antigen-specific antibody production and augments B-cell activation. NDI-101150 inhibits tumor growth in syngeneic tumor models, establishes durable antitumor immune memory, and synergizes with anti-PD1 to enhance exhausted T cell activity and drive tumor regressions. NDI-101150 can be used for the research of cancer, such as breast cancer and colon cancer ^[1] .

HY-149056

GNE-6893	MAP4K Interleukin Related	Cancer
GNE-6893 is an orally active, selective *HPK1* inhibitor with a K_i < 0.02 nM. GNE-6893 enhances T cell receptor signaling in primary human T cells. GNE-6893 increases IL2 production in stimulated primary human T cells. GNE-6893 can be used for the research of chronic refractory cancers ^[1].

HY-146231

SS47	PROTACs MAP4K	Inflammation/Immunology Cancer
SS47, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the antitumor efficacy ^[1].

HY-174357

HPK1 ligand 3-dimethylph tetrahydropyridine	Target Protein Ligand-Linker Conjugates	Cancer
HPK1 ligand 3-dimethylph tetrahydropyridine is a Target Protein Ligand-Linker Conjugate. HPK1 ligand 3-dimethylph tetrahydropyridine can be used to synthesize PROTAC HPK1 Degrader-4 (HY-174135) ^[1].

HY-146231A

SS47 TFA	MAP4K PROTACs	Inflammation/Immunology Cancer
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies ^[1]. SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-160940

HPK1-IN-46	MAP4K	Cancer
HPK1-IN-46 (Compound 36) is an efficient and highly selective *HPK1* reverse indazole inhibitor with an IC₅₀ value of 1.1 nM. HPK1-IN-46 exhibits high selectivity for CDK2, JAK1, and JAK2. HPK1-IN-46 inhibits SLP76 phosphorylation mediated by HPK1, reverses T-cell inhibition, and enhances anti-tumor immunity. HPK1-IN-46 can be used in immunotherapy research for tumors ^[1].

HY-145107

HPK1-IN-19	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-19 (Compound I-47) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor ^[1].

HY-153362

HPK1-IN-34	MAP4K	Cancer
HPK1-IN-34 (Compound 143) is a Hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ of <100 nM ^[1]. HPK1-IN-34 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-178459

*PROTAC HPK1* Degrader-6**	PROTACs MAP4K	Cancer
PROTAC HPK1 Degrader-6 (314) is a highly efficient and effective PROTAC degrader targeting HPK1 (IC₅₀ ＜ 50 nM). PROTAC HPK1 Degrader-6 can be used for the study of leukemia. Red: HPK1 ligand (HY-179196); Blue: E3 ligase CRBN ligand (HY-179197) ^[1].

HY-174135

*PROTAC HPK1* Degrader-4**	PROTACs MAP4K	Cancer
PROTAC HPK1 Degrader-4 (compound E3) is a selective and orally active PROTAC HPK1 degrader with a DC₅₀ of 3.16 nM. PROTAC HPK1 Degrader-4 demonstrates >1000-fold selectivity over GLK. PROTAC HPK1 Degrader-4 promotes immune activation. PROTAC HPK1 Degrader-4 can be used for the study of colon cancer and lymphoma (Pink: ligand for target protein (HY-174355); Blue: ligand for E3 ligase CRBN (HY-45808); Black: Linker (HY-174356); Target protein ligand-linker Conjugate (HY-174357)) ^[1].

HY-174355

HPK1 ligand 3	Ligands for Target Protein for PROTAC MAP4K	Cancer
HPK1 ligand 3 is a ligand for target protein for PROTAC that can be used to synthesize PROTAC HPK1 Degrader-4 (HY-174135) ^[1].

HY-153553

HPK1 antagonist-1	MAP4K	Inflammation/Immunology Cancer
HPK1 antagonist-1 (I-792) is an *Hpk1* antagonist that can be used in the study of cancer and immune disease ^[1].

HY-162544

*PROTAC HPK1* Degrader-2**	PROTACs MAP4K	Cancer
PROTAC HPK1 Degrader-2 (compound 3) is a PROTAC degrader of *HPK1, with the DC₅₀* of 23 nM in human PBMC. PROTAC HPK1 Degrader-2 plays an important role in cancer research ^[1].

HY-145035

HPK1-IN-9	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-9 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) ^[1].

HY-175547

*PROTAC HPK1* Degrader-5**	PROTACs MAP4K ERK Interleukin Related IFNAR	Inflammation/Immunology Cancer
PROTAC HPK1 Degrader-5 is a potent and orally active HPK1 PROTAC degrader (DC50 = 5.0 nM; Dmax ≥ 99%). PROTAC HPK1 Degrader-5 significantly inhibits SLP76 phosphorylation and enhanced ERK pathway activation through degrading HPK1, thereby stimulating IL-2 and IFN-γ release. PROTAC HPK1 Degrader-5 exhibits the ability to overcome the immunosuppressive effects imposed by PGE2, NECA or TGF-β. PROTAC HPK1 Degrader-5 alone efficaciously inhibits tumor growth in an MC38 syngeneic mouse model. PROTAC HPK1 Degrader-5 can be used for the study of tumor (such as colorectal cancer) immunotherapy (Pink: Target protein ligand (HY-175549); Blue: E3 ligand (HY-W023573); Black: Linker; E3 ligand + Linker (HY-175551)) ^[1].

HY-162816

*PROTAC HPK1* Degrader-3**	PROTACs MAP4K	Cancer
PROTAC HPK1 Degrader-3 (compound C3) is an orally effective PROTAC targeting *HPK1* (DC₅₀=21.26 nM). HPK1 is a negative regulator of T cell receptors, which can lead to T cell dysfunction after abnormal activation. PROTAC HPK1 Degrader-3 can inhibit SLP76 and NF-κB signaling pathways and inhibit MAPK signal transduction, and has anticancer activity and immune activation. PROTAC HPK1 Degrader-3 has a certain oral bioavailability and can be combined with PD-L1 antibody therapy to achieve a tumor growth inhibition rate of 65.58%. PROTAC HPK1 Degrader-3 is composed of E3 ligase ligand Thalidomide (HY-14658; blue part), PROTAC linker tert-Butyl 3-oxoazetidine-1-carboxylate (HY-40146; black part), and target protein ligand HPK1-IN-51 (HY-162842; red part); the activity control of the target protein ligand can be HPK1 ligand 1 (HY-162841) ^{[1] ^.}

HY-132150A

HPK1-IN-2 dihydrochloride	MAP4K FLT3 Src	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
HPK1-IN-2 dihydrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC₅₀<0.05 μΜ) with antitumor activity. HPK1-IN-2 dihydrochloride also inhibits Lck (0.05 μΜ<IC₅₀<0.5 μΜ) and Flt3 (IC₅₀<0.05 μΜ) kinase activities ^[1].

HY-168283

HPK1 ligand 2	Ligands for Target Protein for PROTAC	Cancer
HPK1 ligand 2 is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). HPK1 ligand 2 can be used for synthesis DD205-291 (HY-168282) ^[1].

HY-162841

HPK1 ligand 1	Ligands for Target Protein for PROTAC	Cancer
HPK1 ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). HPK1 ligand 1 can be used for synthesis PROTAC PD-L1 degrader-2 (HY-162816) ^[1].

HY-153448

HPK1-IN-36	MAP4K	Cancer
HPK1-IN-36 (compound 2) is a potent *HPK1* inhibitor with an IC₅₀ value of 0.5 nM ^[1].

HY-177272

HPK1-IN-61	MAP4K Bcr-Abl Src	Others
HPK1-IN-61 (Compound 1) is an inhibitor of hematopoietic progenitor kinase 1 (HPK1) (K_i = 0.4 nM) and an inhibitor of Abl (IC₅₀ < 0.51 nM). HPK1-IN-61 also shows inhibitory activity against LCK with an IC₅₀ of 24 nM ^[1].

HY-179196

HPK1 ligand 6	Ligands for Target Protein for PROTAC MAP4K	Cancer
HPK1 ligand 6 is a HPK1 ligand. HPK1 ligand 6 can be used to synthesize PROTAC HPK1 Degrader-6 (HY-178459) ^[1].

HY-179727

*PROTAC HPK1* Degrader-7**	PROTACs MAP4K Interleukin Related IFNAR	Inflammation/Immunology
PROTAC HPK1 Degrader-7 (compound D02) is a potent and selective PROTAC HPK1 degrader with an DC₅₀ of 3.07 nM. PROTAC HPK1 Degrader-7 exhibits selectivity over GLK. PROTAC HPK1 Degrader-7 induces HPK1 degradation in a CRBN- and proteasome-dependent manner. PROTAC HPK1 Degrader-7 inhibits SLP-76 phosphorylation, induces IL-2 and IFN-γ secretion in human primary T cells. PROTAC HPK1 Degrader-7 can be used for immunology research ^[1].

HY-160217

HPK1-IN-41	MAP4K	Cancer
HPK1-IN-41 (compound Z389) is a HPK1 inhibitor with an IC₅₀ value of 0.21 μM. HPK1-IN-41 can be used for the research of preventing and/or treating diseases or conditions associated with HPK1 activity ^[1].

HY-175347

HPK1-IN-60	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-60 (Compound 1) is a HPK1 inhibitor. HPK1-IN-60 can be used for antitumor immunotherapy research ^[1].

HY-156508

HPK1-IN-37	MAP4K	Cancer
HPK1-IN-37 (compound A85) is an inhibitor of HPK1 (IC₅₀=3.7 nM). HPK1-IN-37 can be used for research in HPK1 related disorders or diseases including cancers ^[1].

HY-145109

HPK1-IN-20	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-20 (Compound 106) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor ^[1].

HY-152257

HPK1-IN-31	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-31 (compound 5i) is an orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunoresearch ^[1].

HY-172594

HPK1-IN-57	MAP4K Interleukin Related	Inflammation/Immunology Cancer
HPK1-IN-57 (Compound 10c) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ value of 0.09 nM. HPK1-IN-57 inhibits the activity of HPK1 kinase, hindering the phosphorylation of the downstream adaptor protein SLP76 (IC₅₀ is 33.74 nM) and effectively stimulating the secretion of the T cell activation marker IL-2 (EC₅₀ is 84.24 nM). HPK1-IN-57 is promising for research of tumor immunotherapy ^[1].

HY-144091

HPK1-IN-24	MAP4K	Cancer
HPK1-IN-24 (example 51) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a K_i of 100 nM. HPK1-IN-24 has the potential for cancer research ^[1].

HY-144092

HPK1-IN-25	MAP4K	Cancer
HPK1-IN-25 (example 94) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a enzymatic activity IC₅₀ of 129 nM. HPK1-IN-25 has the potential for cancer research ^[1].

HY-168110

HPK1-IN-52	MAP4K	Cancer
HPK1-IN-52 is a potent and orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ value of 10.4 nM. HPK1-IN-52 exhibits anti-tumor activities ^[1].

HY-163717

HPK1-IN-48	MAP4K	Cancer
HPK1-IN-48 (compound 14g) is a potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor with a IC₅₀ of 0.15 nM. HPK1-IN-48 significantly suppresses the phosphorylation of SLP76 with a IC₅₀ of 27.92 nM ^[1].

HY-145039

HPK1-IN-13	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-13 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-13 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 64) ^[1].

HY-145038

HPK1-IN-12	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-12 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-12 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 85) ^[1].

HY-145040

HPK1-IN-14	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-14 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-14 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 79) ^[1].

HY-145037

HPK1-IN-11	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-11 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-11 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 2) ^[1].

HY-145036

HPK1-IN-10	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-10 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 103) ^[1].

HY-149206

HPK1-IN-33	MAP4K	Cancer
HPK1-IN-33 (compound 21) is a potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor with a K_i value of 1.7 nM. HPK1-IN-33 inhibits the produce of IL-2 with EC₅₀s of 286, >10000 nM in Jurkat WT and Jurkat HPK1 KO cells, respectively ^[1].

Host:	Mouse (2)
Reactivity:	Human (2) Rat (2) Mouse (2) Monkey (2)
Application:	IHC-P (2) WB (2) FC (2) ELISA (2)
Isotype:	IgG1 (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84713

	MAP4K1 Antibody (YA4410) HPK1	WB, IHC-P, FC, ELISA	Human, Mouse, Monkey, Rat
	MAP4K1 Antibody (YA4410) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MAP4K1.

HY-P84713A

	MAP4K1 Antibody (YA4410)(PBS only) HPK1	WB, IHC-P, FC, ELISA	Human, Mouse, Monkey, Rat
	MAP4K1 Antibody (YA4410) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MAP4K1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-146231

SS47		PROTAC Synthesis
SS47, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the antitumor efficacy ^[1].

HY-146231A

SS47 TFA		PROTAC Synthesis
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies ^[1]. SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: